GLP1R and type 2 diabetes mellitus: In conclusion, these new glucose-lowering drugs, especially SGLT2i and GLP1-RA, have opened a range of treatment options not only for T2DM but also for CKD and CVD, including their simultaneous presence in cardiorenal syndrome [29,152].